U.S. markets close in 4 hours 25 minutes
  • S&P 500

    3,840.34
    +41.43 (+1.09%)
     
  • Dow 30

    31,117.18
    +186.66 (+0.60%)
     
  • Nasdaq

    13,418.96
    +221.79 (+1.68%)
     
  • Russell 2000

    2,158.04
    +6.90 (+0.32%)
     
  • Crude Oil

    53.42
    +0.44 (+0.83%)
     
  • Gold

    1,864.10
    +23.90 (+1.30%)
     
  • Silver

    25.70
    +0.39 (+1.52%)
     
  • EUR/USD

    1.2109
    -0.0024 (-0.19%)
     
  • 10-Yr Bond

    1.0960
    +0.0040 (+0.37%)
     
  • GBP/USD

    1.3641
    +0.0007 (+0.05%)
     
  • USD/JPY

    103.6000
    -0.2920 (-0.28%)
     
  • BTC-USD

    34,347.70
    -256.86 (-0.74%)
     
  • CMC Crypto 200

    680.51
    -20.10 (-2.87%)
     
  • FTSE 100

    6,731.26
    +18.31 (+0.27%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

Looking Into Moderna's Return On Capital Employed

Benzinga Insights
·1 min read

During Q3, Moderna's (NASDAQ: MRNA) reported sales totaled $157.91 million. Despite a 92.52% in earnings, the company posted a loss of $235.12 million. In Q2, Moderna brought in $66.35 million in sales but lost $122.13 million in earnings.

What Is ROCE?

Changes in earnings and sales indicate shifts in Moderna’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Moderna posted an ROCE of -0.09%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

View more earnings on MRNA

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Moderna is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

For Moderna, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q3 Earnings Insight

Moderna reported Q3 earnings per share at $-0.59/share, which did not meet analyst predictions of $-0.43/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.